Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Tonsillitis Treatment Market size is expected to expand at around 6.5% CAGR during the forecast period i.e., between 2025-2037.
The growth of the market can be attributed to the rising incidences of flu around the world and high germ exposure of people living in under-developed nations. On an average, in the United States, 5% to 20% of the population gets the flu. The disease results in more than 32 million people outpatient visits each year. Along with these, growing prevalence of infections caused by virus and bacteria, detrimental changes in the lifestyle and increasing shift towards unhealthy eating habits among people are also expected to drive market growth in the near future. Furthermore, escalating government initiatives to spread awareness about antibiotic and over-the-counter treatment in rural and semi-urban areas is projected to provide ample growth opportunities to the market in the forthcoming years.
Tonsillitis Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Number of Incidences of Flu Around the World
- High Germ Exposure of People in Under Developed Nations
Challenges
- Lack of Regulations for the Certification of Medications in Lower Income Economies
Tonsillitis Treatment Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.5% |
|
Regional Scope |
|
Tonsillitis Treatment Segmentation
The market is segmented by treatment into antibiotics, over-the-counter drugs, homeopathy medicines, tonsillectomy and others, out of which, the antibiotics segment is anticipated to hold the largest share in the tonsillitis treatment market on account of the characteristics of these drugs such as slowing down infection growth, speedy recovery, prevention of occurrence of infection and ease of consumption. According to the Centers for Disease Control and Prevention (CDC), 266.1 million courses of antibiotics are dispersed to outpatients in U.S. community pharmacies. Moreover, the segment for over-the-counter drugs is predicted to witness noteworthy growth over the forecast period, which can be credited to the increasing usage of these medication for treating ailments in children and young teenagers. Apart from these, the effectiveness of these medication in relieving symptoms caused by viral infections are also assessed to fuel the growth of this market segment in the future.
Our in-depth analysis of the global tonsillitis treatment market includes the following segments
|
By Disease Type |
|
|
By Disease Cause |
|
|
By Treatment
|
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportTonsillitis Treatment Industry - Regional Synopsis
North America Market Statistics
North America industry is expected to hold largest revenue share by 2037, on the back of presence of well-established healthcare facilities, major market players and high levels of awareness regarding different medications in the region. In addition to these, high government spending on the healthcare sector is also expected to fuel the region’s market growth in the coming years.
APAC Market Analysis
Moreover, the tonsillitis treatment market in Asia Pacific is anticipated to witness noteworthy growth during the forecast period, which can be ascribed to the large patient pool, improper maintenance of cleanliness in South Asian countries and increasing private investments for establishment of hospitals in the region. As per a report by UNICEF, India accounted for 90% of the people in South Asia and 1.2 billion people in the world that defecated in the open. This situation contributed to the deaths of 100,000 children under five years in the country.
Companies Dominating the Tonsillitis Treatment Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- GlaxoSmithKline plc
- Reckitt Benckiser Group plc
- Sun Pharmaceutical Industries Ltd
- Bayer AG
- AstraZeneca plc
- Novartis AG
- Walgreen Co.
- Prestige Brands Holdings, Inc
- Perrigo Company
In the News
- January 06, 2021: More than 20 leading pharmaceutical companies including Bayer AG, announced the launch of AMR Action Fund, a partnership that aims to bring 2-4 new antibiotics to the patients by the end of 2030.
Author Credits: Radhika Pawar
- Report ID: 3123
- Published Date: Dec 24, 2024
- Report Format: PDF, PPT
